Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Medicinsk behandling af lungecancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Martin Reck
  • Anders Mellemgaard
  • Joachim von Pawel
  • Maya Gottfried
  • Igor Bondarenko
  • Ying Cheng
  • Kostas Zarogoulidis
  • Alexander Luft
  • Jaafar Bennouna
  • José Barrueco
  • Hesham Aboshady
  • Julia Hocke
  • Rolf Kaiser
  • Jean-Yves Douillard
  • LUME-Lung 1 Study Group
Vis graf over relationer

OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. Progression-free survival was significantly improved with nintedanib+docetaxel in the overall population and overall survival was significantly improved in the pre-specified analysis of patients with adenocarcinoma. We evaluated the frequency of characteristic adverse events (AEs) commonly seen with existing anti-angiogenic agents.

MATERIALS AND METHODS: The incidence and intensity of AEs were evaluated in all patients who received at least one dose of study medication (N=1307) and for the two main histologies: adenocarcinoma (n=653) and squamous cell carcinoma (SCC; n=553). AEs of special interest were analyzed by category, preferred term, and worst CTCAE grade and included perforation, hypertension, bleeding, thromboembolic events, and skin disorders.

RESULTS AND CONCLUSION: The incidence of patients with all-grade gastrointestinal (GI) perforations was low and balanced between arms (0.5% in both) and across histologies; the incidence of non-GI perforations was 1.2% with nintedanib+docetaxel versus 0.2% with placebo+docetaxel. The incidence of some events was higher with nintedanib+docetaxel versus placebo+docetaxel; hypertension (3.5% vs 0.9%), rash (11.0% vs 8.1%), and cutaneous adverse reactions (13.0% vs 10.7%). Rash and cutaneous adverse reactions were predominantly Grade 1-2 with both treatments. The incidence of all-grade bleeding was also slightly higher in nintedanib+docetaxel-treated patients (14.1% vs 11.6%) driven by between-treatment differences in the SCC subpopulation; most events were Grade 1-2. The proportion of patients with a thromboembolic event was low and comparable between arms for all grades (5.1% vs 4.6%) and Grade ≥3 (2.1% vs 3.1%). Safety evaluation of the LUME-Lung 1 study showed that the frequency of AEs commonly associated with other anti-angiogenic agents was lower with nintedanib+docetaxel. Survival benefits from addition of nintedanib to docetaxel in patients with adenocarcinoma after first-line therapy can be achieved alongside a manageable safety profile.

TidsskriftLung cancer
StatusUdgivet - 12 aug. 2015

ID: 45681234